In this review of the retinal vein occlusion (RVO), I have summarized recent advances on several controversial and clinically important topics: classification of RVO into six distinct clinical entities; pathogeneses and demographic characteristics of various types of RVO; differentiation of non-ischemic from ischemic central retinal vein occlusion (CRVO); differentiation of hemi-CRVO (HCRVO) from major branch RVO (BRVO); and the course, complications and management of various types of RVO

Maintenance of pupillary dilatation is necessary for success of scleral buckling procedures. The efficacy of 0.03% flurbiprofen in preventing intraoperative miosis was evaluated by a prospective randomized, double-masked controlled trial of 60 patients. Thirty patients received 0.03% flurbiprofen 6 times at 15 minute intervals 90 minutes preoperatively in addition to the routine dilation regimen. The treated group had a mean pupillary decrease of 1.88 mm and the control group had a decrease of 1.57 mm (p > 0.05). Flurbiprofen did not affect the pupillary size at any step of the surgery. Factors such as age of the patient, lens status, number of cryo applications, duration of surgery, and the size and extent of buckle were assessed. The use of flurbiprofen did not affect the mean pupillary change for any of these groups. Preoperative use of flurbiprofen does not significantly decrease intraoperative miosis during scleral buckling procedures

Nanophthalmos is a rare form of congenital hypermetropia, in which, the individual is at a high risk of developing angle-closure glaucoma. We report a family of nanophthalmos affecting a brother and sister, as confirmed by biometry. Genetic analysis revealed an autosomal recessive mode of inheritance. The sister developed angle-closure glaucoma, which was refractory to medical and laser therapy. She underwent surgical interventions which resulted in complications. The clinical presentation, management, and complications encountered are discussed

Phacolytic glaucoma has traditionally been treated with intracapsular lens extraction to avoid any anaphylaxis. Various mechanisms have been described for the rise of intraocular pressure in these cases. The present study was undertaken to evaluate the response of extracapsular cataract extraction (ECCE) with posterior chamber intraocular lens implantation (PC IOL) in five cases of phacolytic glaucoma that occurred between March 1989 and August 1990. A planned extracapsular cataract extraction with can-opener capsulectomy was done in all the cases with placement of a sulcus-fixated modified J-loop Sinskey design intraocular lens. With a mean follow-up period of two years, all patients (100%) maintained a normal postoperative intraocular pressure of less than 20 mm Hg without any additional medical therapy. The final best-corrected visual acuity in 4 cases (80%) was 6/12 or better, while in one case it was 6/24 due to a senile maculopathy. These results show that ECCE with PC IOL implantation is a safe and efficacious method of visual rehabilitation in cases of phacolytic glaucoma

A new free radical scavenger, U74006F (Upjohn Company, Kalamazoo, MI, USA) was studied to determine if it would have a beneficial effect on preventing intraocular pressure (IOP) spikes and reducing blood-aqueous barrier (BAB) breakdown in rabbits after argon laser trabeculoplasty (ALT). The post-ALT IOP averaged 24.7 mm Hg (+/- 3.8 mm Hg; N = 6) and 30.3 mm Hg (+/- 6.9 mm Hg; N = 7) at 1 hour (p = 0.097) and 22.7 mm Hg (+/- 1.9) and 27.3 mm Hg (+/- 7.0 mm Hg) at 3 hours in the U74006F and vehicle groups (p = 0.137), respectively. By 48 hours, the IOP averaged 12.8 +/- 2.2 mm Hg in the U74006F group and 12.4 +/- 2.4 mm Hg in the vehicle group (P = 0.757). The aqueous fluorescein permeability (AFP) between lasered and unlasered eyes was determined for the U74006F and vehicle-treated groups by aqueous fluorophotometry. Prelaser or baseline AFP was determined for the U74006F (-0.236 +/- 0.236) and vehicle (-0.145 +/- 0.237) groups (p = 0.505). At day 2 posttreatment, the U74006F group and the placebo group both reported similar AFP of 5.109 +/- 4.831 and 5.680 +/- 4.280 (p = 0.827), respectively. At one week post-ALT, AFP for the U74006F group (0.109 +/- 0.367) had returned close to baseline, while that of the vehicle group (0.426 +/- 0.511) was still quite elevated (p = 0.220). U74006F appears to be beneficial in the prevention of acute elevation of IOP following ALT but not in the prevention of Blood-Aqueous Barrier (BAB) breakdown.

In 24 patients with irreversible lagophthalmos, gold weights ranging from 0.8 to 1.7 g were implanted in the upper lids, under local anaesthesia. With a follow-up period ranging from 2 1/2 to 4 years (average, 3 years), the results of the implantation were gratifying in 23 patients. While corneal irritation and epiphora was reduced and the loaded upper eyelid allowed patients to blink voluntarily